INSIGHTS ON DRUG DEVELOPMENT

• Lowering The Lipid Barrier To RNA-LNP Therapeutics

  Industry experts discuss current and future trends, formulating successful lipid compositions and navigating the constantly evolving genomic medicine landscape.

• Successful Wetting For Filter Integrity Testing In Volume-Restricted Systems

  Filters with a qualified retention for bacteria, mycoplasma or viruses are commonly used in many pharmaceutical processes. In a validated GMP process, these filters must be routinely tested for integrity. 

• Multi-Attribute Method Analysis: Moving Toward Mainstream

  Employing the Multi-Attribute Method based on liquid chromatography-mass spectrometry analysis represents a critical advancement in evaluating the complexity of biotherapeutic molecules.

• Support For Your Production Challenges

  Ensure your manufacturing operations run smoothly and efficiently by collaborating with experts to tackle production, processing, or quality control issues.

• Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight

  7/23/2024

  By using an optimized transient transfection platform, drug developers can accelerate their characterization and early development activities, facilitating continuity for a drug's scale-up.

• Biopharma Resilience: CDMOs Secure Supply Chain Management

  10/21/2022

  Learn how SanKav Pharmaceuticals provides available medicine to market through available components, resources and raw materials that support on-time production lines and biomanufacturing processes.

• Establishing A Robust Workflow To Identify High-Performing Clones

  1/13/2023

  Cell line development is a complex, labor intensive, and multistep process. Learn about a platform and host cell line that minimize the risk and timeline to develop high-performing clones.

• Development Of Chemically Defined Medium For Vero Cells

  8/29/2022

  Gain insight into a new developed, fully chemically defined and animal component free culture medium which supports Vero cell growth in static and in bioreactor cultures.

• SPR Assays To The Assess Similarity Between Innovator And Biosimilar Versions of Nivolumab (Opdivo®)

  9/2/2022

  Learn more about developed and qualified SPR assays to characterize the binding and affinity of biosimilar and innovator nivolumab for all seven Fc gamma receptors, FcRn and PD-1.